Conjugate Includes Potentiator Or Composition Comprising Conjugate Includes Potentiator Patents (Class 424/180.1)
-
Patent number: 11166898Abstract: A human growth hormone fusion protein has enhanced thermal stability. The human growth hormone fusion protein has the amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 4. A gene encoding the human growth hormone fusion protein has E. coli codon-optimized nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6. A recombinant vector includes the aforementioned gene. A host cell is transformed with the aforementioned recombinant vector. A method for producing in a host cell a human growth hormone fusion protein includes transforming a host cell with the aforementioned recombinant vector. The human growth hormone fusion protein may improve skin wrinkle and maintain skin elasticity. As the human growth hormone fusion protein has thermal stability and also has an effect of improving skin wrinkle and increasing the effect of maintaining skin elasticity, it can be advantageously used as a raw material of cosmetics.Type: GrantFiled: January 9, 2017Date of Patent: November 9, 2021Assignees: NEXGEN BIOTECHNOLOGIES, INC.Inventors: Sun Kyo Lee, Seong Ran Lee, Han Bong Ryu, Tae Won Choi, Tae Hyun Kim
-
Patent number: 11123330Abstract: Methods of inhibiting mutant EGFR and methods of treating a subject afflicted with a lung cancer having a mutant EGFR, having for example a C797 mutation, are described. The methods comprise administering to a cell or a subject in need thereof a therapeutically effective amount of a compound selected from 3-(1,3-benzoxazol-2-yl)-7-(diethylamino)-2H-chromen-2-one and a structurally related analog thereof; midostaurin; and AZD7622 and a structurally related analog thereof; and mixtures thereof. Compositions and combinations comprising the compounds of the disclosure as well as uses are also provided.Type: GrantFiled: September 28, 2018Date of Patent: September 21, 2021Assignee: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Igor Stagljar, Jamie Snider, Punit Saraon
-
Patent number: 9221888Abstract: The invention relates to peptides including DEDE(SSD)nDEG indicated by SEQ NO. 1, RRRDEDE(SSD)nDEG indicated by SEQ No. 2, RRRGDEDE(SSD)nDEG indicated by SEQ No. 3, and LKKLKKLDEDE(SSD)nDEG indicated by SEQ NO. 4, wherein n is an integer from 2 to 20. The invention also relates to phosphorylating these peptides at multiple amino acid sites by employing casein kinases. These phosphorylated peptides may be used in various applications such as forming mineralized collagen fibrils and biomimetic composites for use in tissue repair and regeneration.Type: GrantFiled: November 13, 2013Date of Patent: December 29, 2015Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Elia Beniash, Charles S. Sfeir
-
Publication number: 20150147345Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.Type: ApplicationFiled: June 12, 2013Publication date: May 28, 2015Inventor: Marek Kwiatkowski
-
Patent number: 8974792Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: April 6, 2012Date of Patent: March 10, 2015Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Publication number: 20140348754Abstract: Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell.Type: ApplicationFiled: May 14, 2014Publication date: November 27, 2014Inventors: DEVIN WILEY, ANDREW CLARK, MARK E. DAVIS
-
Patent number: 8871908Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: November 7, 2012Date of Patent: October 28, 2014Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 8846874Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: GrantFiled: November 13, 2004Date of Patent: September 30, 2014Assignee: Hanmi Science Co., LtdInventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 8821884Abstract: The invention provides compositions and methods for the targeted bacteriostatic and antibacterial agents and for treatment of sepsis caused by infectious diseases, such as bacterial and fungal diseases. In one aspect, the invention provides methods and compositions for decreasing the levels of LPS in the circulation of an individual, e.g., a human patient with sepsis, e.g., gram negative septic shock. In one aspect, the invention is directed to chimeric proteins comprising the MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. In one aspect, the invention is directed to chimeric proteins comprising fragments or altered form of MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. The invention also provides pharmaceutical compositions comprising the chimeric polypeptides of the invention, and methods of making and using them, including methods for ameliorating or preventing sepsis.Type: GrantFiled: July 27, 2005Date of Patent: September 2, 2014Assignee: The Regents of the University of CaliforniaInventors: Theo N. Kirkland, III, Sunganya Viriyakosol
-
Patent number: 8753641Abstract: The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them.Type: GrantFiled: July 20, 2009Date of Patent: June 17, 2014Assignee: University of ZurichInventors: Roger Ariel Alberto, Pascal Jean-Marie Hafliger
-
Publication number: 20140093522Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.Type: ApplicationFiled: May 16, 2012Publication date: April 3, 2014Applicant: KONINKLIJKE PHILIPS N.V.Inventors: Marc Stefan Robillard, Hendricus Marie Janssen, Wolter Ten Hoeve, Ronny Mathieu Versteegen, Raffaella Rossin
-
Publication number: 20130189287Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs.Type: ApplicationFiled: December 21, 2012Publication date: July 25, 2013Applicants: Innate PharmaInventors: Innate Pharma, Paul Scherrer Institut
-
Patent number: 8481003Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods.Type: GrantFiled: November 27, 2012Date of Patent: July 9, 2013Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg, Bo B. Lundberg
-
Patent number: 8388973Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: December 30, 2010Date of Patent: March 5, 2013Assignee: Genentech, Inc.Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
-
Patent number: 8343496Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods.Type: GrantFiled: September 27, 2010Date of Patent: January 1, 2013Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg, Bo B. Lundberg
-
Patent number: 8277803Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: August 16, 2011Date of Patent: October 2, 2012Assignee: Hoffman-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Patent number: 8268317Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.Type: GrantFiled: August 11, 2009Date of Patent: September 18, 2012Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, David M. Goldenberg, Sung-Ju Moon
-
Patent number: 8163291Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.Type: GrantFiled: May 19, 2009Date of Patent: April 24, 2012Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 8119101Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.Type: GrantFiled: May 28, 2010Date of Patent: February 21, 2012Assignees: The Ohio State University, Immunomedics, Inc.Inventors: John C. Byrd, David M. Goldenberg, Hans J. Hansen
-
Patent number: 8114417Abstract: The present invention discloses amino acid sequences and nucleic acid sequences relating to a Streptococcus pneumoniae surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa). The PPP exhibits the ability to reduce colonization of pneumococcal bacteria. Thus the present invention also pertains to compositions for the treatment and prophylaxis of infection or inflammation associated with bacterial infection.Type: GrantFiled: August 31, 2006Date of Patent: February 14, 2012Assignee: Wyeth LLCInventors: Bruce A. Green, Amy W. Masi
-
Patent number: 8084029Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.Type: GrantFiled: April 20, 2011Date of Patent: December 27, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 8013128Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: March 4, 2009Date of Patent: September 6, 2011Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 7914784Abstract: The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.Type: GrantFiled: April 10, 2007Date of Patent: March 29, 2011Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Olivier Leger, Alain Duflos, Jean-François Haeuw, Alain Beck
-
Patent number: 7851599Abstract: The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognizing the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.Type: GrantFiled: April 4, 2007Date of Patent: December 14, 2010Assignee: Philogen S.p.A.Inventors: Andreas Menrad, Hans Dietrich Menssen, Karola Wagner
-
Patent number: 7846445Abstract: The present invention provides methods of using unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities, and the uses thereof. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: GrantFiled: March 6, 2007Date of Patent: December 7, 2010Assignee: Amunix Operating, Inc.Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
-
Patent number: 7829064Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates compositions in therapeutic and/or diagnostic methods.Type: GrantFiled: November 12, 2003Date of Patent: November 9, 2010Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg, Bo B. Lundberg
-
Patent number: 7811564Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: January 28, 2004Date of Patent: October 12, 2010Assignee: Proscan RX PharmaInventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffet
-
Publication number: 20100203066Abstract: The present invention provides polymeric linkers containing pyridyl disulfide moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed.Type: ApplicationFiled: September 15, 2007Publication date: August 12, 2010Applicant: ENZON PHARMACEUTICALS, INC.Inventors: Hong Zhao, Prasanna Reddy, Jing Xia
-
Patent number: 7731978Abstract: Forms of GAS25 (streptolysin O) which are not toxic but which still maintain the ability to induce protection against S. pyogenes are useful in vaccine compositions to induce protection against S. pyogenes.Type: GrantFiled: December 19, 2008Date of Patent: June 8, 2010Assignee: Novartis AGInventors: Giuliano Bensi, Immaculada Margarit Y Ros, Emiliano Chiarot, Guido Grandi, Maria Scarselli
-
Patent number: 7670605Abstract: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.Type: GrantFiled: August 15, 2008Date of Patent: March 2, 2010Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Donald L. Elbert, Ronald Schoenmakers
-
Patent number: 7666424Abstract: This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.Type: GrantFiled: October 17, 2002Date of Patent: February 23, 2010Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Nai-Kong Cheung, Hong-Fen Guo
-
Patent number: 7615225Abstract: The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity.Type: GrantFiled: September 25, 2006Date of Patent: November 10, 2009Assignee: Active Biotech ABInventors: Goran Forsberg, Eva Erlandsson, Per Antonsson, Bjorn Walse
-
Patent number: 7601817Abstract: The present invention relates to recombinant protein PEG positional isomers. More specifically, it relates to PEG positional isomers of an antibody having specificity for antigenic determinants of human tumor necrosis factor alpha (TNF?). More specifically, it relates to PEG positional isomers of CDP870. The present invention also relates to compositions comprising the PEG positional isomers and therapeutic uses of the composition for treating a disease medicated by TNF? including acute and chronic immune and immunoregulatory disorders and rheumatoid-or osteo-arthritis.Type: GrantFiled: May 28, 2003Date of Patent: October 13, 2009Assignee: UCB Pharma S.A.Inventor: Ned M. Mozier
-
Patent number: 7498034Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascu lar endothelium.Type: GrantFiled: November 6, 2001Date of Patent: March 3, 2009Assignee: Cancer Research Technology LimitedInventors: Roy Bicknell, Lukasz Huminiecki
-
Patent number: 7491706Abstract: The present invention provides a series of artificial CpG-containing single-stranded oligodeoxynucleotides (ODNs), each of which is consisted of single-stranded oligodeoxynucleotide DNA molecule containing one or more CpG(s), wherein said ODNs can stimulate human peripheral blood mononuclear cell (PBMC) to produce antiviral substances. These ODNs can protect the cells against the attack from virus, wherein said virus is preferably selected from the group consisted of influenza virus and single-stranded positive strand RNA virus such as SARS virus, hepatitis C virus, dengue virus and Japanese encephalitis virus. Moreover, the antiviral use of artificial CpG ODNs and its use for treating and preventing viral infection are also provided.Type: GrantFiled: July 26, 2004Date of Patent: February 17, 2009Assignee: Changchun Huapu Biotechnology Co., Ltd.Inventors: Yongli Yu, Liying Wang
-
Patent number: 7435790Abstract: The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence: DhcGN NDE SNI SFK EK. The invention relates also to a composition comprising the mentioned peptide.Type: GrantFiled: March 10, 2003Date of Patent: October 14, 2008Assignee: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventor: Peter F. Muehlradt
-
Patent number: 7413739Abstract: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.Type: GrantFiled: October 25, 2005Date of Patent: August 19, 2008Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Donald Elbert, Ronald Schoenmakers
-
Patent number: 7387772Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: April 5, 2002Date of Patent: June 17, 2008Assignee: Immunimedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Patent number: 7344703Abstract: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or virulence of a pathogenic mycobacterium, and methods of treating disease conditions associated with a pathogenic mycobacterium, particularly by administering an inhibitor of a mycobacterial sulfation pathway protein. The present invention further provides genetically modified mycobacteria having a defect in a sulfation pathway enzyme gene; and immunogenic compositions that include such genetically modified mycobacteria.Type: GrantFiled: September 1, 2005Date of Patent: March 18, 2008Assignee: The Regents of the University of CaliforniaInventors: Carolyn R. Bertozzi, Spencer J. Williams, Joseph D. Mougous
-
Patent number: 7320791Abstract: A novel anti-polyethylene glycol monoclonal antibody and its preparation are disclosed. Such an antibody can be used for determining polyethylene glycol concentration in vitro or accelerating the clearance of a polyethylene glycol containing compound from the blood circulation in the human body thereby reducing the toxicity associated with the polyethylene glycol containing conjugate. The antibody is particularly useful in cancer therapy where the therapeutic agent is selectively delivered to the tumor by increasing the tumor/blood ratio of the polyethylene glycol containing compound.Type: GrantFiled: July 15, 2003Date of Patent: January 22, 2008Assignee: Academia SinicaInventors: Steve Roffler, Tian-Lu Cheng, Pin-Yi Wu
-
Patent number: 7291673Abstract: The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.Type: GrantFiled: June 4, 2001Date of Patent: November 6, 2007Assignees: Eidgenossiche Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Donald Elbert, Ronald Schoenmakers
-
Patent number: 7070778Abstract: The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal antibody is administered with either ?-(1,3)-glucan like laminarin or a oligo-?-(1,3)-glucan and a pharmaceutically acceptable carrier, to patients suffering from cancer are described.Type: GrantFiled: October 30, 2003Date of Patent: July 4, 2006Assignee: Laboratoire Goemar SAInventors: Jean-Claude Yvin, Edouard Panak, Vaclav Vetvicka
-
Patent number: 6977075Abstract: The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder that is associated with an intracellular pathogen by administering, to a subject, a molecular conjugate that includes a photosensitizer (a term used herein to refer to a light activatable compound) and a targeting moiety, the targeting moiety being capable of targeting the conjugate to the intracellular pathogen.Type: GrantFiled: April 14, 2003Date of Patent: December 20, 2005Assignee: The General Hospital CorporationInventors: Tayyaba Hasan, Jerome Gross, Gerard J. Nau
-
Patent number: 6974580Abstract: Novel mycobacterial sulfation pathway proteins and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting growth and/or virulence of a pathogenic mycobacterium, and methods of treating disease conditions associated with a pathogenic mycobacterium, particularly by administering an inhibitor of a mycobacterial sulfation pathway protein. The present invention further provides genetically modified mycobacteria having a defect in a sulfation pathway enzyme gene; and immunogenic compositions that include such genetically modified mycobacteria.Type: GrantFiled: July 13, 2004Date of Patent: December 13, 2005Assignee: The Regents of the University of CaliforniaInventors: Carolyn R. Bertozzi, Spencer J. Williams, Joseph D. Mougous
-
Patent number: 6806253Abstract: A therapeutical vaccine complex having activity specific for Helicobacter bacteria as well as non-specific immunomodulation activity for regulating the natural defenses of the body. The drug is also useful for preventing relapses, particularly in cases of resistance to conventional treatment. The drug essentially consists of RNA, selective membrane fractions of microbial germs, particular amino acid sequences, sodium chloride and a steroidal anti-inflammatory in predetermined proportions enabling simultaneous delivery of antibiotics and frenosecretories. Said drug is particularly suitable for treating digestive tract diseases caused by Helicobacter (antral gastritis, duodenal ulcers, gastric ulcers, oesophagitis, hepatitis) and preventing stomach cancer and degenerative infectious MALT (mucosa-associated lymphoid tissue) lymphoma, as well as coronary diseases directly or indirectly dependent on Helicobacter infections.Type: GrantFiled: August 25, 1998Date of Patent: October 19, 2004Inventor: Fernand Narbey Torossian
-
Patent number: 6756037Abstract: The present invention is directed to polymer conjugates of biologically active agents and methods of preparing the same. In preferred aspects of the invention, the conjugates are of the formula wherein G is a linear or branched polymer residue such as a polyethylene glycol and B is a residue of an amine-containing or a hydroxyl-containing biologically active moiety such as Ara-C.Type: GrantFiled: March 29, 2001Date of Patent: June 29, 2004Assignee: Enzon, Inc.Inventors: Richard B. Greenwald, Yun H. Choe
-
Patent number: 6737057Abstract: Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor antagonist. The compounds and compositions of the invention may be used to selectively suppress the immune system to treat symptoms associated with immune disorders such as allergies, transplanted tissue rejection and autoimmune disorders including lupus, rheumatoid arthritis and multiple sclerosis.Type: GrantFiled: January 7, 1997Date of Patent: May 18, 2004Assignee: The University of Tennessee Research CorporationInventor: Habib Zaghouani
-
Patent number: 6660267Abstract: Compositions and methods are described for preventing and treating sepsis in humans and animals. Surgical patients, low birth weight infants, and burn and trauma victims can be treated prophylactically. Methods for treating acute infections are provided with advantages over current therapeutic approaches.Type: GrantFiled: September 12, 1994Date of Patent: December 9, 2003Assignee: Promega CorporationInventor: Sean B. Carroll
-
Patent number: 6610298Abstract: The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder that is associated with an intracellular pathogen by administering, to a subject, a molecular conjugate that includes a photosensitizer (a term used herein to refer to a light activatable compound) and a targeting moiety, the targeting moiety being capable of targeting the conjugate to the intracellular pathogen.Type: GrantFiled: October 15, 1999Date of Patent: August 26, 2003Assignee: The General Hospital CorporationInventors: Tayyaba Hasan, Jerome Gross, Gerard J. Nau
-
Patent number: 6573242Abstract: The invention relates to a S-(2,3-dihydroxypropyl)-cysteine peptide which has two long-chain fatty acids bonded in the form of esters at the dihydroxypropyl group, and which has the following sequence: Dhc GN NDE SNI SFK EK (SEQ ID No 1) 1 5 10 The invention relates also to a composition comprising the mentioned peptide.Type: GrantFiled: June 16, 1999Date of Patent: June 3, 2003Assignee: Gesellschaft fuer BiotechnologischeInventor: Peter F. Muehlradt